Cryoablation for T1a RCC Linked With Good Long-Term Outcomes
No residual malignancy was found in 98% of patients treated with percutaneous cryoablation.
No residual malignancy was found in 98% of patients treated with percutaneous cryoablation.
Investigators confirmed that prostate cancer recurrence was truly localized using biopsy and imaging before considering salvage whole-gland cryoablation.
Partial gland ablation of MRI-invisible prostate cancer has been controversial.
Percutaneous cryoablation for cT1b renal tumors is associated with a higher rate of local disease recurrence compared with partial nephrectomy, new data suggest.
Increased cancer-specific mortality seen with heat-based thermal ablation versus cryoablation for tumor size 3.1 to 4 cm
Among patients with CKD stage 3 or higher, the mean estimated glomerular filtration rate remained stable during the 12 months following thermal ablation for localized renal cell carcinoma.
Salvage cryotherapy is emerging as a viable local treatment option for prostate cancer that recurs following radiation treatment.
In a propensity score-based study, prostate cryoablation added to androgen deprivation therapy (ADT) improved failure-free survival and survival without castration-resistant disease compared with ADT alone.
In a study, patients who underwent salvage cryotherapy for radiorecurrent prostate cancer had cancer-specific and metastasis-free survival rates of 81% and 78%, respectively, at 12 years.
Cryoablation also cuts the need for opioids at 24 hours post-treatment and at 3 months.